Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Berkeley HeartLab commercialized advanced blood and genetic tests for cardiovascular disease risk. Their offerings included expanded lipid panels and apolipoprotein E genotyping. The company partnered with Lawrence Berkeley National Laboratory to bring research-grade diagnostics into clinical use. No drug or therapeutic clinical trials; focus was on diagnostic accuracy and utility in patient management.
The company was acquired by Quest Diagnostics in 2011; post-acquisition, its operations were integrated into Quest's broader lab services.
There are no current clinical results as the entity no longer operates independently.
In May 2017, Quest paid $6 million to resolve allegations related to kickbacks and unnecessary testing practices at the former subsidiary; there was no admission of wrongdoing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Berkeley HeartLab.